1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 2:Rescue therapy outcomes with GP IIb/IIIa inhibitors: abciximab versus tirofiban/eptifibatide
Outcome Abciximab % (95% CI) I2 Tirofiban/Eptifibatide % (95% CI) I2 P Value Postoperative clinical stroke 14.0 (8.0–25.0) 50 13.0 (4.0–33.0) 77 .86 Postoperative infarct on imaging 28.0 (19.0–39.0) 44 37.0 (9.0–76.0) 81 .67 Postoperative hemorrhage 7.0 (4.0–10.0) 0 14.0 (6.0–31.0) 26 .12 Perioperative morbidity from stroke/hemorrhage 12.0 (8.0–18.0) 4 8.0 (4.0–16.0) 3 .30 Perioperative mortality from stroke/hemorrhage 6.0 (4.0–10.0) 0 6.0 (3.0–12.0) 0 .16 Long-term good neurologic outcome 85.0 (79.0–89.0) 0 78.0 (69.0–85.0) 0 .15 Long-term morbidity 14.0 (9.0–21.0) 15 18.0 (11.0–29.0) 19 .37 Recanalization rate 66.0 (58.0–74.0) 32 83.0 (68.0–91.0) 60 .05